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Abstract
Hemodialysis (HD) and continuous venovenous hemodialysis (CVVHD) have an unproven role in the
management of carbamazepine overdose. Albumin-enhanced CVVHD may accelerate carbamaze-
pine (CBZ) clearance, but no pharmacokinetic data has been reported for traditional CVVHD without
albumin enhancement. In addition, it is unclear whether the active CBZ-epoxide metabolite is
removed with either mode of dialysis. We present a case of CBZ intoxication successfully managed
with sequential HD and CVVHD. The CBZ half-life during CVVHD was 14.7 hours, compared with the
patient’s endogenous half-life of 30.8 hours. The CBZ-epoxide half-life was 3.2 hours during HD. We
conclude that HD and CVVHD provide effective clearance of CBZ and the epoxide metabolite and
should be considered in the management of an acute toxic ingestion.
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INTRODUCTION
Carbamazepine (CBZ) overdose and toxicity can lead to
neurologic dysfunction, respiratory compromise, cardiac
arrhythmias, and death.1 Initial management of acute in-
gestion involves limiting absorption of the drug utilizing
gastric lavage and oral activated charcoal. Development of
an ileus from the anticholinergic effects of CBZ can delay
absorption so that peak serum levels may be seen up to 96
hours postingestion.2 Traditionally, extracorporeal therapies
were considered of limited utility given that at therapeutic
concentrations CBZ is about 80% to 85% protein-bound
and has a large volume of distribution estimated between
0.5 to 2 L/kg.3 Case reports of charcoal hemoperfusion,
high-flux hemodialysis (HD), and albumin-enhanced con-
tinuous venovenous hemodialysis (CVVHD) have shown
some success,4–9 but typically only describe serum levels of
the drug, which are widely influenced by variable hepatic
metabolism and renal excretion. Since dialysate levels of
CBZ rarely have been measured, improved clearance with
HD and CVVHD is inferred but not substantiated. Further-
more, little is known about whether extracorporeal therapy
effectively removes the major active metabolite, carbamaze-
pine-10,11 epoxide (CBZ-E).
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We describe a case of acute CBZ overdose that was
successfully managed by HD followed immediately by
CVVHD and report pharmacokinetic analysis of CBZ and
its epoxide metabolite for both modalities.
CASE REPORT
A 32-year-old, 48 kg female was brought to an emergency
department 2 hours after ingestion of 32 g of CBZ in an
apparent suicide attempt. She had not been taking CBZ
chronically. Upon presentation she was obtunded and un-
responsive with a Glasgow Coma Scale of 3. Her initial
blood pressure was 132/88 mmHg with a heart rate of 94/
minute, respiratory rate of 14/minute, and oxygen satura-
tion level of 95% on room air. Cardiopulmonary exam was
unremarkable. Bowel sounds were absent. She was noted to
have flaccid muscle tone, and exhibited diffuse hypo-
reflexia. Occulocephalic and corneal reflexes were absent.
Gastric lavage was not performed. A nasogastric tube
was placed followed by administration of 50 g of activated
charcoal. Over the next several hours, the patient had
3 tonic clonic seizures, became hypoxic, and required
intubation. She became hypotensive to 74/46 and was
treated with volume resuscitation and intravenous
vasopressor therapy. Initial serum drug levels 2.5 hours
after ingestion were: CBZ 32.9 mg/mL (therapeutic 4 to
12 mg/mL), ethanol 190 mg/dL, and acetaminophen
45 mg/mL (therapeutic range: 10 to 30 mg/mL). Urine
screening for pregnancy and drugs of abuse was nega-
tive. An ECG revealed a normal QRS interval at 86 ms.
Subsequent serum CBZ concentrations were: 42.7 ug/mL
at 4 hours postingestion, 67mg/mL at 11 hours and
480mg/mL; at 16 hours. Other lab work revealed sodium
143 mmol/L, bicarbonate 23 mmol/L, creatinine 0.8 mg/dL,
and calcium 8.7 mg/dL with normal liver function tests
except for an ALT of 42 IU/L.
Due to the continued rise in serum CBZ concentrations
with associated neurologic impairment and cardio-
vascular instability, the patient was transferred to our
institution and HD was initiated 23 hours after ingestion
with a F-200 NR dialyzer (Fresenius Medical Care North
America, Waltham, MA, USA) (surface area 2.0 m2, ul-
trafiltration coefficient 62 mL/h/mmHg) with a blood flow
rate of 350 mL/min and a dialyzate flow rate of 700 cc/
min. Treatment was continued for 3 hours. This was fol-
lowed immediately by CVVHD using a Braun Diapact
with a F-160 NR dialyzer, a blood flow rate of 200 mL/
min, a dialyzate flow rate of 4000 mL/h (83 mL/kg/h), and
a regional citrate anticoagulation protocol.10 No net ul-
trafiltration was performed with either therapy.
The CVVHD was discontinued after 38 hours of therapy
at which point she was awake and interactive, extubated,
and off vasopressors. At the time of CVVHD discontinua-
tion, the serum CBZ level was 11.5mg/mL. The EEG mon-
itoring revealed no epileptiform activity. She remained
nonoliguric throughout her course. She was discharged
on hospital day five with no residual sequela.
Pre/postdialyzer and effluent samples were collected dur-
ing HD and CVVHD and were assayed for CBZ and CBZ-E
by a fluorescence polarization immunoassay. Clearance by
HD and CVVHD was determined with the equations:
Clearance ðHDÞ ¼ Pre dialyzer conc post dialyzer conc
Pre dialyzer conc
 Blood flow rate
Transmembrane clearance ðCVVHDÞ
¼ Effluent CBZ concentration
Prefilter CBZ concentration
 Dialyzate flow rate
CBZ half-life was determined from the slope of the re-
gression line of the serum CBZ concentration-time profile
for each segment of therapy/no therapy (Fig. 1).
Calculated CBZ clearance during HD was 77.2 mL/min
based on samples taken during the last hour when con-
centrations were within the assay range of the laboratory.
At the beginning of HD, CBZ levels could not be
accurately quantified by the clinical laboratory as levels
were above the upper limits of the assay (480 mg/mL). As
a result, CBZ half-life during HD could not be accurately
estimated. Total CBZ-E clearance was 147 mL/min at the
























Figure 1 Serum carbamazepine levels during hemodialysis,
continuous venovenous hemodialysis, and after extracorporeal
therapy was ended. Regression lines during continuous veno-
venous hemodialysis (CVVHD) and after therapy are shown.
Carbamazepine clearance with HD and CVVHD
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apparent half-life of CBZ-E during HD was 3.2 hours.
During CVVHD, CBZ and CBZ-E saturation coefficients
were 0.36 and 0.70, resulting in CVVHD transmembrane
clearances of 24.0 mL/min and 46.4 mL/min respectively.
CBZ half-life was 14.7 hours during CVVHD therapy.
Once CVVHD was discontinued, the patient’s endoge-
nous half-life of CBZ was 30.8 hours.
DISCUSSION
We describe a case of severe acute CBZ ingestion with
neurologic, respiratory, and cardiovascular compromise
that was successfully managed with HD followed by
CVVHD, a sequence of therapies not previously reported
in the literature. Initial dosing of CBZ results in a half-life
of 25 to 65 hours, while chronic dosing leads to autoin-
duction of the hepatic cytochrome P450 enzyme CYP3A4
with a decreased half-life of 12 to 17 hours.11 Hepatic
metabolism of the drug produces the active CBZ-E me-
tabolite that is about 50% protein bound12 and has a half-
life of 6.9 hours.13 Several reports indicate that toxicity
can occur with elevated CBZ-E levels, even in the setting
of therapeutic CBZ levels.14–16
Our patient, who had not been taking CBZ chronically,
had an endogenous CBZ half-life of 30.8 hours, similar
to numerous reports of 31 to 37.7 hours with single dose
ingestion.2,11,17 CVVHD greatly enhanced CBZ clearance
with a 50% reduction in half-life of the drug, thereby
potentially reducing the ICU stay. The sieving coefficient
of 0.36 obtained during CVVHD suggests a larger fraction
of unbound CBZ than would be anticipated at therapeutic
concentrations, 0.15 to 0.2. This is likely due to satura-
tion of protein binding sites in the setting of an acute in-
toxication. The sieving coefficient of CBZ-E was 0.70,
essentially twice that of the parent compound and was
also amenable to removal through CVVHD therapy with
a shorter half-life than what has been reported in the
literature.13,18 Thus, while charcoal hemoperfusion was
originally thought to be needed for CBZ removal, our data
indicate that CVVHD can be an effective alternative therapy,
particularly in hemodynamically unstable patients.
Askenazi published a case report4 of albumin-
enhanced CVVHD with an albumin concentration of
4.5 g/dL in the dialyzate. They observed a CBZ half-life
between 7 and 8 hours, which was twice as fast as we
attained in our study using albumin-free dialyzate. Aske-
nazi used a dialysate flow rate of 3 L per 1.73 m2, com-
pared with our dialyzate flow rate of 4.4 L per 1.73 m2.
However, direct CBZ dialytic clearance was not measured
in their case report and the patient’s native CBZ clearance
was unknown, thus making it difficult to determine the
relative benefit of that therapy. In the in vitro assessment
of albumin enhanced CVVHD, Churchwell et al. reported
that increased dialyzate flow substantially improved CBZ
clearance independently of whether 2.5% or 5% albumin
enhanced dialyzate was used.19 Therefore, CVVHD with
high dialyzate flow, but without albumin enhancement
as shown in the present study, can provide significant
clearance without the incremental costs.
Kielstein et al.8 reported a CBZ clearance of 59 mL/min
in one of the only studies containing pharmacokinetic
data in high-flux HD. However, this is likely an under-
estimate, as they used a batch dialysis system, in which
a subsequent study20 revealed contamination of fresh
dialyzate with spent dialyzate when used for toxin removal
in a patient like ours, who did not have renal failure.
In summary, our data show that both HD and CVVHD
greatly enhance overall clearance of CBZ and its metab-
olite, CBZ-E. We suggest that both modalities be consid-
ered in cases of acute large quantity CBZ ingestion
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